SANTA CLARA, California, March 30, 2017 /PRNewswire/ -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, will showcase scientific expertise at the American Association of Cancer Research (AACR) 2017 Annual Meeting April 1-5 in Washington, D.C.
CrownBio will present data on its latest scientific developments including the impact of intestinal microbiota on anti-PD-L1 immunotherapy, the development of primary tumor allograft models for preclinical testing of PARP inhibitors, and the validation of a panel of patient-derived xenograft and cell line models for prostate cancer, among others.
There will be 14 CrownBio scientific posters presenting their data from April 2nd to April 5th at AACR 2017 Annual Meeting.
Representatives from the CrownBio Business Development and Marketing teams will welcome delegates at booth 1847 for live demonstrations of the enhanced version of OncoExpress™, the Company's one stop search engine for oncology models including proprietary data on PDX, syngeneics, and cell line derived xenografts.
"We are excited to present every year at AACR an increasing number of scientific posters with cutting edge data and technologies," said Laurie Heilmann, SVP of Global Strategy, Marketing and Business Development. "CrownBio continues to demonstrate both our deep commitment to global cancer research and our contribution as a leading provider of preclinical oncology solutions."
"This year we are particularly excited to debut our enhanced digital engagement platform including the OncoExpress mobile app which brings data into the hands of our clients," said Gavin Cooper, Executive Director of Marketing at CrownBio. "We continue to facilitate our clients' research with more groundbreaking tools throughout 2017."
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
SOURCE Crown Bioscience Inc.